Stanozolol Hilma Biocare USA
$79.00
Product Short Description
Stanozolol 10 mg 100 Tabs Hilma Biocare USA deliversΒ stanozololΒ (C21H32N2O), the 17Ξ±-methyl-5Ξ±-dihydrotestosterone pyrazole derivative exhibiting lean anabolic response (~320:30 ratio) with zero aromatization, at exact 10 mg strength replicating historical Winstrol formulation. Domestic U.S. production eliminates customs exposure servingΒ DEA Schedule IIIΒ compliant institutional channels through verified performance networks.β
Product Overview
Hilma Biocare USA’s Stanozolol 10 mg presentsΒ stanozolol, featuring unique pyrazoline ring substitution conferring exceptional oral bioavailability (~9 hour half-life) and SHBG displacement alongside dry anabolic effects, in small round white scored tablets matchingΒ Winstrol (Winthrop)Β morphology for institutional catalog integration across DEA-registered platforms. The 100-tablet HDPE bottle configuration supportsΒ CIII-compliant inventory reconciliationΒ under 21 CFR 1304.22 requiring detailed Schedule III tracking for institutional handlers maintaining federal compliance.β
U.S.-domiciled GMP manufacturingΒ maintains molecular specifications (MW 328.49) distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing documented across analytics. This authentic presentation serves institutional buyers requiringΒ Form 222 triplicate documentationΒ across U.S. jurisdictions, eliminating international sourcing risks.β
Hilma Stanozolol positions exclusively withinΒ verified DEA Schedule III ecosystemsΒ targeting licensed institutional clientele underΒ 21 CFR 1301.13.
Brand & Manufacturer Information
Hilma Biocare USAΒ manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiringΒ DEA registrant verification. Stanozolol 10 mg anchors Hilma’s non-aromatizing oral catalog alongside Anavar/Primo maintaining dosage standardization while authenticating supply chain legitimacy versus powder-pressed alternatives rejected by institutional handlers.
Domestic warehousing supportsΒ Form 222 platformsΒ eliminating customs risk while serialized batch documentation verifies 10 mg potency distinguishing Hilma from non-pharmaceutical origins.β
Active Compound Information
ContainsΒ stanozololΒ (17Ξ±-methyl-5Ξ±-androstan-17Ξ²-ol-[3,2-c]pyrazole), DHT-derived anabolic steroid exhibitingΒ pyrazoline ring fusionΒ conferring 3x testosterone anabolic potency with minimal androgenic activity characteristic of 17Ξ±-alkylated non-aromatizing steroids.Β DEA Schedule IIIΒ classification reflects joint/lipid stress potential and moderate hepatotoxicity requiring lipid monitoring.β
10 mg strength matchesΒ historical Winstrol 10 mgΒ reference while 100-tablet count supports institutional packaging. Molecular formula C21H32N2O;Β WADA S1.1a prohibitedΒ globally.β
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Stanozolol 10 mg 100 Tabs Hilma Biocare USA |
| Active Compound | Stanozolol (C21H32N2O)Β β |
| Strength | 10 mg per round scored tabletΒ β |
| Quantity | 100 tablets per HDPE bottle |
| Form | Oral scored tablets (Winstrol equivalent) |
| Category | DEA Schedule III controlled substance |
| Appearance | White, round, single-scored |
| Molecular Weight | 328.49 g/mol |
| Half-Life | ~9 hoursΒ β |
| Label Elements | “10 mg”, CIII warnings, serialized lot |
Quality Control & Testing Standards
10 mg stanozololΒ mandatesΒ USP <621> potency assayΒ (HPLC 95-105%),Β USP <711> dissolution,Β USP <905> uniformity, andΒ pyrazoline verificationΒ confirming pharmaceutical-grade specifications. Hilma batch records documentΒ C21H32N2O identityΒ distinguishing GMP production from underground conversions.β
100-tablet CIII configurationΒ incorporates USP <671> HDPE barriers with child-resistant closure satisfyingΒ 21 CFR 310.310(a). Stability maintainsΒ ICH Q1A(R2)Β 36-month shelf-life.
Intended Use & Market Positioning
Stanozolol 10 mg servesΒ DEA-registered CIII institutional researchersΒ managing non-aromatizingΒ Schedule III anabolic inventoriesΒ through encrypted fulfillment requiringΒ Form 222 accountability.
Zero protocols, cycles, or outcomes representedΒ maintaining commercial CIII positioning.
Legal & Regulatory Disclaimer
Stanozolol constitutes DEA Schedule IIIΒ underΒ 21 USC Β§812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties).Β Institutional buyers assume Form 222/DEA licensing liability;Β no medical claims provided.β
You must be logged in to post a review.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisqueΒ vestibulum amet elit ut volutpat.
Reviews
There are no reviews yet.